[Dabrafenib plus trametinib for advanced melanoma]

Gonzalez L, Oubiña M, Sebastián García Martí, Pichon-Riviere A, Augustovski F, Alcaraz A, Bardach A, Ciapponi A
Record ID 32018001290
Spanish
Original Title: Dabrafenib, trametinib y cobimetinib para el tratamiento del melanoma
Authors' recommendations: CONCLUSIONS High quality evidence shows that the use of dabrafenib plus trametinib in patients with irresecable or metastatic melanoma with BRAF V600 mutation is associated to a longer overall survival, progression-free survival and a better overall response rate when compared with dabrafenib or vemurafenib as monotherapies. No studies comparing this combination with other treatment options currently considered as first line such ipilimumab, anti-PD1 antibodies have been found, although there is evidence from indirect comparisons that suggests there would be no differences in overall survival versus nivolumab, pembrolizumab antibodies or the vemurafenib/cobimetinib combination. The clinical practice guidelines from the main oncology societies consider the combination among the treatment options for the mentioned population; its use as first line is preferred in case of need for a rapid clinical response based on symptoms and/or disease tumor burden. Also several public and private health sponsors consulted consider the use of both drugs in combination in patients with advanced melanoma.
Details
Project Status: Completed
Year Published: 2017
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Melanoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: <p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.